# Identification of potentially deleterious mutations in gastric cancer using patient-derived xenograft models

**Authors:** Luke Kong, Jie Wang, Junqi Zheng, Xihua Yang, Ruifang Sun, Jiahui Kou, Yujie Yao, Feng Li, Fuhua Wang, Sutang Guo

PMC · DOI: 10.3389/fgene.2025.1571535 · 2026-01-29

## TL;DR

This study used patient-derived xenograft models to identify harmful mutations in gastric cancer, preserving tumor characteristics and revealing potential targets for treatment.

## Contribution

The study introduces a method using PDX models and WES to identify conserved, potentially harmful mutations in gastric cancer.

## Key findings

- Nine PDX models were established, with 7 reaching the third generation, showing a 45% engraftment success rate.
- 28 somatic mutations were conserved across generations, with 10 predicted to be deleterious.
- Four mutations (PTPRK, PIK3CB, LRP1B, IGF2R) were identified as significantly affecting protein stability.

## Abstract

This study aimed to identify novel mutations associated with the progression of gastric cancer by establishing patient-derived xenograft (PDX) models and performing comprehensive genomic characterization of these PDX models and their corresponding primary tumors.

Fresh gastric cancer tissue samples were collected from 20 patients who underwent surgical resection at Shanxi Cancer Hospital and were subsequently implanted into NOD-SCID mice to establish PDX models. Histopathological features were evaluated using hematoxylin and eosin (H&E) staining. Whole-exome sequencing (WES) was performed on both primary tumors and their corresponding F1-PDX and F3-PDX tumors, focusing on mutations within 559 cancer-related genes. Predictive tools, including SIFT, Polyphen2_HVAR, Polyphen2_HDIV, and Mutation Taster, were utilized to identify potentially deleterious mutations, while I-Mutant and MUpro were employed to assess protein stability.

Nine gastric cancer PDX models were successfully established, with seven models propagated to the third generation (F3-PDX), achieving an initial engraftment success rate of 45%. The latency of tumor establishment significantly decreased with each successive generation. The histological characteristics of the primary tumors were well preserved in the PDX models. WES of the three selected models revealed key mutated genes in primary tumors (F0), including IRS2, BLM, PDE4DIP, NUMA1, MYH9, TP53, PIK3CD, ERCC5, and ASXL1. A total of 28 somatic mutations were conserved across all three generations (F0, F1-PDX, and F3-PDX) in these models, representing a conservation rate of 43.75% (28/64). Among these conserved mutations, 10 were identified as potentially deleterious by multiple bioinformatics algorithms. Mutations in PTPRK (p.L988S), PIK3CB (p.F934L), LRP1B (p.A1912T), and IGF2R (p.G2052R) were predicted to significantly decrease protein stability.

This study demonstrated that PDX models effectively preserve the biological and genetic characteristics of primary gastric tumors, underscoring their utility in studying tumor heterogeneity. The integrated analysis of longitudinal WES data from primary tumors and matched PDXs enabled the identification of a core set of conserved, potentially deleterious mutations. The four prioritized mutations (PTPRK, PIK3CB, LRP1B, and IGF2R) provide new insights into the genetic landscape of gastric cancer and represent promising candidates for the development of targeted therapeutic strategies.

## Linked entities

- **Genes:** IRS2 (insulin receptor substrate 2) [NCBI Gene 8660], BLM (BLM RecQ like helicase) [NCBI Gene 641], PDE4DIP (phosphodiesterase 4D interacting protein) [NCBI Gene 9659], NUMA1 (nuclear mitotic apparatus protein 1) [NCBI Gene 4926], MYH9 (myosin heavy chain 9) [NCBI Gene 4627], TP53 (tumor protein p53) [NCBI Gene 7157], PIK3CD (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta) [NCBI Gene 5293], ERCC5 (ERCC excision repair 5, endonuclease) [NCBI Gene 2073], ASXL1 (ASXL transcriptional regulator 1) [NCBI Gene 171023], PTPRK (protein tyrosine phosphatase receptor type K) [NCBI Gene 5796], PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291], LRP1B (LDL receptor related protein 1B) [NCBI Gene 53353], IGF2R (insulin like growth factor 2 receptor) [NCBI Gene 3482]
- **Diseases:** gastric cancer (MONDO:0001056)

## Full-text entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, ERCC5 (ERCC excision repair 5, endonuclease) [NCBI Gene 2073] {aka COFS3, ERCC5-201, ERCM2, UVDR, XPG, XPGC}, MYH9 (myosin heavy chain 9) [NCBI Gene 4627] {aka BDPLT6, DFNA17, EPSTS, FTNS, MATINS, MHA}, LRP1B (LDL receptor related protein 1B) [NCBI Gene 53353] {aka LRP-1B, LRP-DIT, LRPDIT}, NUMA1 (nuclear mitotic apparatus protein 1) [NCBI Gene 4926] {aka NMP-22, NUMA}, BLM (BLM RecQ like helicase) [NCBI Gene 641] {aka BS, MGRISCE1, RECQ2, RECQL2, RECQL3}, PDE4DIP (phosphodiesterase 4D interacting protein) [NCBI Gene 9659] {aka CMYA2, MMGL}, IRS2 (insulin receptor substrate 2) [NCBI Gene 8660] {aka IRS-2}, IGF2R (insulin like growth factor 2 receptor) [NCBI Gene 3482] {aka CD222, CI-M6PR, CIMPR, M6P-R, M6P/IGF2R, MPR 300}, PTPRK (protein tyrosine phosphatase receptor type K) [NCBI Gene 5796] {aka R-PTP-kappa}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, PIK3CD (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta) [NCBI Gene 5293] {aka APDS, IMD14, IMD14A, IMD14B, P110DELTA, PI3K}, ASXL1 (ASXL transcriptional regulator 1) [NCBI Gene 171023] {aka BOPS, MDS}
- **Diseases:** SCID (MESH:D053632), gastric cancer (MESH:D013274), Cancer (MESH:D009369)
- **Chemicals:** eosin (MESH:D004801), H&amp;E (-), hematoxylin (MESH:D006416)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** p.F934L, p.L988S, p.A1912T, p.G2052R

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12895051/full.md

---
Source: https://tomesphere.com/paper/PMC12895051